Our case is the first to identify a KAT6B-KANSL1 gene fusion in a uterine leiomyoma, a finding that contributes to the evolving molecular landscape of leiomyomas that may allow for tailored therapeutic intervention or development of targeted therapy. This evidence concerns the gene KAT6B and leiomyoma.